Efficacy and Safety of Camrelizumab in Real-World Prospective Study
This observational real-world study is designed to evaluate the efficacy and safety of camrelizumab for the treatment of Chinese NSCLC patients.
Non-small Cell Lung Cancer
DRUG: Camrelizumab
AE,Grade 3-5, Safety of the general population:Serious Adverse Events (AE)ï¼ŒGrade 3-5., From April 1, 2021 to Septeember 30, 2024
pCR, Neoadjuvant therapy population: pathological complete response rate (pCR)., From April 1, 2021 to December 30, 2024|MPR, Neoadjuvant population: main pathological response rate (MPR), From April 1, 2021 to December 30, 2024|R0 resection rate, Neoadjuvant therapy population: R0 resection rate., From April 1, 2021 to December 30, 2022|ORR, Advanced non-small cell lung cancer: objective response rate (ORR)., From April 1, 2021 to December 30, 2022|PFS, Advanced non-small cell lung cancer: progression-free survival., From April 1, 2021 to December 30, 2022|OS, Advanced non-small cell lung cancer: Overall survival., From April 1, 2021 to December 30, 2022
Camrelizumab is a humanized antibody for cancer immunotherapy. The National Medical Products Administration (NMPA, China) approved camrelizumab as a first-line treatment of certain patients with NSCLC. This is a multicenter non-interventional study, NSCLC patients who have been treated with camrelizumab will be included. The main objective of this study is to evaluate the efficacy and safety of camrelizumab in the clinical practice.